by Admin | Mar 23, 2026 | News
MHRA published Field Safety Notices: 9–13 March 2026 on 17 March 2026, listing device-related notices within its alerts, recalls, and safety-information framework. The agency continues to publish these weekly summaries as part of its public safety communications....
by Admin | Mar 23, 2026 | Safety Signals
MHRA said Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure after a potential manufacturing error may have led to Amlodipine 5 mg Tablets being packed inside a carton labeled as Ramipril 5 mg Capsules. The agency said...
by Admin | Mar 23, 2026 | News
FDA announced on 19 March 2026 that it approved Wegovy HD (semaglutide 7.2 mg) for weight loss and long-term weight maintenance in certain adults. The agency said the decision came 54 days after filing and marked the fourth approval under the Commissioner’s National...
by Admin | Mar 23, 2026 | Inspections & Compliance
FDA’s 2026 Safety and Availability Communications page for biologics says it was developed to provide the public with important information about the safety and availability of biological products. FDA’s broader “What’s New for Biologics” page also surfaces current...
by Admin | Mar 23, 2026 | Regulatory Updates
MHRA approved deuruxolitinib for severe alopecia areata in adults and explicitly said it would continue to keep the medicine’s safety and effectiveness under close review. Meanwhile, EMA listed new ESMP training for industry and published continued CVMP activity for...
